EB 001

Drug Profile

EB 001

Alternative Names: EB-001

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bonti
  • Class Bacterial proteins; Bacterial toxins
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glabellar lines
  • Phase I Musculoskeletal pain

Most Recent Events

  • 06 Jun 2017 Pharmacodynamics data from a preclinical study in Musculoskeletal pain released by Bonti
  • 03 May 2017 Interim efficacy data from a phase IIa trial in Glabellar lines released by Bonti
  • 18 Apr 2017 Bonti plans a phase II trial for Musculoskeletal pain in the second half of 2017 (NCT03193593)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top